FIELD: medicine.
SUBSTANCE: invention relates to a compound of the formula (I) or its pharmaceutically acceptable salt, having inhibitory activity against LSD1, an LSD1inhibitor, a pharmaceutical composition and an antitumor agent based on them, a method for the treatment of a patient with acute human myelocytic leukemia and small cell lung cancer, as well as their use in the production of such an antitumor agent. In the general formula (I), ring A is a 5-9-element monocyclic, bridged cyclic or spirocyclic nitrogen-containing saturated heterocyclic group optionally additionally containing 1 nitrogen atom, ring B is phenyl or 9-element bicyclic aromatic heterocyclic group with 1-3 nitrogen atoms, R1 is nitro or cyano, R2 is halogen, R3 is unsubstituted amino, mono- or di(C1-C6 alkyl)amino, (C3-C7 cycloalkyl)amino or C1-C6 alkyl, R4 is halogen, unsubstituted C3-C7 cycloalkyl or C1-C8 alkyl, unsubstituted or substituted OH or cyclobutyl, R5 is hydrogen or C1-C6 alkyl, R6 is hydrogen, l is an integer from 0 to 1, m is an integer from 0 to 2, and n is an integer from 0 to 3, where if m is 2, two R3 can be the same or different, and if n is from 2 to 3, from two to three R4 can be the same or different.
EFFECT: provision of compounds of the formula (I) or their pharmaceutically acceptable salts with inhibitory activity against LSD1.
12 cl, 42 tbl, 300 ex
Title | Year | Author | Number |
---|---|---|---|
NEW BIPHENYL COMPOUND OR ITS SALT | 2016 |
|
RU2726622C2 |
METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF AN LSD 1INHIBITOR BASED ON THE INSM1 EXPRESSION | 2018 |
|
RU2789449C2 |
ANTITUMOR EFFECT ENHANCER USING NEW BIPHENYL COMPOUND | 2018 |
|
RU2765153C2 |
NOVEL NICOTINAMIDE DERIVATIVE OR ITS SALT | 2011 |
|
RU2576623C2 |
NITRILE-CONTAINING ANTIVIRAL COMPOUNDS | 2021 |
|
RU2820150C2 |
NITRILE-CONTAINING ANTIVIRAL COMPOUNDS | 2021 |
|
RU2786722C1 |
DIPEPTIDYL PEPTIDASE-IV INHIBITORS | 2010 |
|
RU2574410C2 |
PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | 2008 |
|
RU2479584C2 |
MENIN-MLL INTERACTION INHIBITORS | 2017 |
|
RU2799820C2 |
Authors
Dates
2022-01-26—Published
2018-05-25—Filed